Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00700778 · ClinicalTrials.gov registry record · NA
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
A NA study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT00700778 is a NA study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT00700778, a NA study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women with BRCA1 mutations. PURPOSE: This clinical trial is studying recombinant human chorionic gonadotropin in preventing breast cancer in premenopausal women with BRCA1 mutations.
Interventions
- GENETIC microarray analysis
- OTHER laboratory biomarker analysis
- OTHER immunohistochemistry staining method
- PROCEDURE needle biopsy
- BIOLOGICAL recombinant human chorionic gonadotropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-07 |
| Est. Completion | 2014-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00700778
The ClinicalTrials.gov registry entry for NCT00700778 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00700778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00700778 about?
NCT00700778 is a clinical study titled "Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women with BRCA1 mutations. PURPOSE: This clinical trial is studying recombinant human chorionic gonadotropin in prevent...
What is the current status of trial NCT00700778?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2008-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00700778?
The interventions under investigation include: microarray analysis (GENETIC), laboratory biomarker analysis (OTHER), immunohistochemistry staining method (OTHER), needle biopsy (PROCEDURE), recombinant human chorionic gonadotropin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00700778?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.